Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
After securing $2.1 billion this May, AI-driven drug designer Isomorphic Labs is back with more money—a lot more—securing the industry’s largest private fundraise ever.
Follow along as BioSpace tracks job cuts and restructuring initiatives.
Analysts are broadly confident that povetacicept will notch an approval in IgA nephropathy by the end of the month, setting up “the next wave” for Vertex Pharmaceuticals.
At the 2026 Clinical Trials on Alzheimer’s Disease conference, AriBio reported that AR1001 slowed cognitive decline more than placebo in patients not taking other drugs for the disease.
Sellas Life Sciences’ investigational cancer vaccine prolonged median overall survival by over nine months compared to standard of care in a Phase 3 trial for difficult-to-treat acute myeloid leukemia.
A licensing pact with Stipple Bio was one of two announced by Eli Lilly on Monday, after the up to $1.5 billion buyout of blood cancer-focused Calytrix Bio.
It’s been a long road to financial stability for Genetix Biotherapeutics, the rebranded name of bluebird bio following its February 2025 sale to two private equity firms, but on Monday the biotech estimated full year 2026 sales will reach $500 million.
Marrow Therapeutics aims to address safety and accessibility obstacles in genetic medicines by delivering therapies straight to bone marrow cells.
Women held 29% of biotech board seats in fiscal 2025 but just 8.8% of CEO roles, highlighting uneven progress across industry leadership spots.
Helus Pharma’s psilocin-based HLP003 significantly reduced symptoms of major depressive disorder in the adjuvant setting in a Phase 3 trial but was tripped up in the stock market by three serious adverse events.